Chronic Lymphocytic Leukemia Treatment Market Research Report - Global Forecast till 2023

Chronic Lymphocytic Leukemia Treatment Market Research Report: by Type (Indolent & Aggressive), by Treatment (Chemotherapy, Targeted Drug Therapy, Immunotherapy & Bone Marrow Transplant), by End User (Hospitals & Clinics & Others) - Global Forecast Till 2023

ID: MRFR/Pharma/5435-HCR | February 2021 | Region: Global | 90 pages

Market Scenario:


Global Chronic Lymphocytic Leukemia (CLL) Treatment Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 7.9 Billion in 2017 and is projected to grow at a CAGR of 19% over the forecast period. Chronic Lymphocytic Leukemia is a type of cancer that affects a specific type of white blood cell known as lymphocyte.


The factors such as rising prevalence of leukemia as well as CLL, increasing research & development activities and technological advancements related to the treatment are expected to propel the growth of the market. However, the high cost of treatment and stringent government regulations can hamper the market growth over the forecast period.


Segmentation:


The Global Chronic Lymphocytic Leukemia Treatment Market has been segmented into type, treatment and end user. The market, on the basis of type, has been segmented into indolent CLL and aggressive CLL.


The market, by treatment, has been segmented into chemotherapy, targeted drug therapy, immunotherapy and bone marrow transplant.


The market, by end user, has been segmented into hospitals & clinics, diagnostic laboratories, research institutes and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The chronic lymphocytic leukemia treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European chronic lymphocytic leukemia treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The chronic lymphocytic leukemia treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The chronic lymphocytic leukemia treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.


 Key players:


F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, CELGENE CORPORATION, Genmab A/S, Teva Pharmaceutical Industries Ltd., Genentech, Inc., Genzyme Corporation, AbbVie Inc., Gilead, Novartis AG, Johnson & Johnson Services, Inc., AstraZeneca, ONO PHARMACEUTICAL CO., LTD., TG Therapeutics, Inc., Ziopharm Oncology, Inc. and others are some of the key players in the global chronic lymphocytic leukemia treatment market.


Regional Market Summary:


Global Chronic Lymphocytic Leukemia Treatment Market Share (%), by Region, 2017


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports


Geographically, the Americas is anticipated to dominate the global chronic lymphocytic leukemia treatment market owing to rising prevalence of leukemia and presence of major market players. According to a report published by the Leukemia & Lymphoma Society in 2018, every 3 minutes one person in the US is diagnosed with blood cancer (leukemia).


Europe is expected to hold the second largest position in the global chronic lymphocytic leukemia treatment market. The market growth in this region is attributed to rising research and development activities in the field of leukemia. The chronic lymphocytic leukemia treatment market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the rising prevalence of leukemia and growing demand for treatment of the disease. According to a report published by the World Health Organization in 2017, 8,904 leukemia deaths were reported in Japan.


The Middle East & Africa are expected to hold the least share of the market. The market growth in this region is expected to be driven by a developing healthcare infrastructure.


Global Chronic Lymphocytic Leukemia Treatment Market, by Type:



  • Indolent CLL

  • Aggressive CLL


Global Chronic Lymphocytic Leukemia Treatment Market, by Treatment:



  •       Chemotherapy

  •       Targeted Drug Therapy

  •        Immunotherapy

  •       Bone Marrow Transplant


Global Chronic Lymphocytic Leukemia Treatment Market, by End User:



  •      Hospitals and Clinics

  •      Diagnostic Laboratories

  •      Research Institutes

  •      Others


Global Chronic Lymphocytic Leukemia Treatment Market, by Region:



  • Americas

  •      North America

  •      US

  •      Canada

  •       South America

  • Europe



  •       Western Europe

  •       Germany

  •        France

  •        Italy

  •        Spain

  •        UK

  •        Rest of Western Europe

  •        Eastern Europe



  • Asia-Pacific



  •       Japan

  •       China

  •       India

  •       Australia

  •       South Korea

  •       Rest of Asia-Pacific



  • The Middle East & Africa



  •       Middle East

  •        Africa


Global Chronic Lymphocytic Leukemia Treatment Market, by Key Players:



  •       Hoffmann-La Roche Ltd

  •       GlaxoSmithKline plc

  •       CELGENE CORPORATION

  •       Genmab A/S

  •       Teva Pharmaceutical Industries Ltd.

  •       Genentech, Inc.

  •       Genzyme Corporation

  •       AbbVie Inc.

  •       Gilead

  •       Novartis AG

  •       Johnson & Johnson Services, Inc.

  •       AstraZeneca

  •       ONO PHARMACEUTICAL CO., LTD.

  •       TG Therapeutics, Inc.

  •       Ziopharm Oncology, Inc.


Intended Audience:



  • Pharmaceutical Companies

  • Research Laboratories

  • Oncology Laboratories

  • Healthcare Organizations


 



Frequently Asked Questions (FAQ) :


Chronic Lymphocytic Leukemia Treatment Market had a valuation of USD 7.9 billion in 2017.

Chronic Lymphocytic Leukemia Treatment Market would record a CAGR of 19% during the forecast period of 2018 to 2023.

Chronic Lymphocytic Leukemia Treatment Market would have end users like research institutes, diagnostic laboratories, hospitals & clinics, and others.

Chronic Lymphocytic Leukemia Treatment Market has been discussed on the basis of treatments like targeted drug therapy, chemotherapy, immunotherapy, and bone marrow transplant.

Americas are leading the Chronic Lymphocytic Leukemia Treatment Market.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Equipment Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type

6.1 Introduction

6.2 Indolent CLL

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

6.3 Aggressive CLL

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

Chapter 7. Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment

7.1 Introduction

7.2 Chemotherapy

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.3 Targeted Drug Therapy

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.4 Immunotherapy

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

7.5 Bone Marrow Transplant

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

Chapter 8. Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User

8.1 Introduction

8.2 Hospitals and Clinics

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

8.3 Diagnostic Laboratories

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

8.4 Research Institutes

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

8.5 Others

Market Estimates & Forecast, by Region, 2018–2023

Market Estimates & Forecast, by Country, 2018–2023

Chapter 9. Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Region

9.1 Introduction

9.2 Americas

9.2.1North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 F. Hoffmann-La Roche Ltd

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 GlaxoSmithKline plc

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 CELGENE CORPORATION

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Genmab A/S

11.4.1 Company Overview

11.4.2 Type Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Teva Pharmaceutical Industries Ltd.

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Genentech, Inc.

11.6.1 Company Overview

11.6.2 Type Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Genzyme Corporation

11.7.1 Overview

11.7.2 Type Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 AbbVie Inc.

11.8.1 Overview

11.8.2 Type Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Gilead

11.9.1 Overview

11.9.2 Type Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Novartis AG

11.10.1 Overview

11.10.2 Type Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Johnson & Johnson Services, Inc.

11.11.1 Overview

11.11.2 Type Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 AstraZeneca

11.12.1 Overview

11.12.2 Type Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 ONO PHARMACEUTICAL CO., LTD.

11.13.1 Overview

11.13.2 Type Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 TG TREATMENT, INC.

11.14.1 Overview

11.14.2 Type Overview

11.14.3 Financials

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.15 ZIOPHARM ONCOLOGY, INC.

11.15.1 Overview

11.15.2 Type Overview

11.15.3 Financials

11.15.4 Key Developments

11.15.5 SWOT Analysis

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Chronic Lymphocytic Leukemia Treatment (CLL) Industry

Chapter 13. Appendix

LIST OF TABLES:

Table 1 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market Synopsis, 2018–2023

Table 2 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market Estimates and Forecast, 2018–2023 (USD Million)

Table 3 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Region, 2018–2023(USD Million)

Table 4 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023 (USD Million)

Table 5 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million)

Table 6 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2 018–2023 (USD Million)

Table 7 North America: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023 (USD Million) Table 8 North America: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million)

Table 9 North America: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million)

Table 10US: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023(USD Million)

Table 11US: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023(USD Million)

Table 12 US: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023(USD Million)

Table 13Canada: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023(USD Million)

Table 14Canada: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million)

Table 15Canada: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million)

Table 16South America: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023 (USD Million)

Table 17South America: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million)

Table 18South America: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million)

Table 19Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023(USD Million)

Table 20Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million)

Table 21Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million)

Table 22Western Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023 (USD Million) Table 23 Western Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million) Table 24Western Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million)

Table 25 Eastern Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023 (USD Million) Table 26 Eastern Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million) Table 27 Eastern Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million)

Table 28 Asia-Pacific: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type,2018–2023 (USD Million) Table 29 Asia-Pacific: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million) Table 30 Asia-Pacific: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million)

Table 31 Middle East & Africa: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023 (USD Million) Table 32 Middle East & Africa: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million) Table 33 Middle East & Africa: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million) LIST OF FIGURES:

Figure 1 Research Process

Figure 2 Market Structure for Global Chronic Lymphocytic Leukemia Treatment (CLL) Market

Figure 3 Market Dynamics for Global Chronic Lymphocytic Leukemia Treatment (CLL) Market

Figure 4 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Type, 2017

Figure 5 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Treatment, 2017

Figure 6 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by End User, 2017

Figure 7 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Distribution Channel, 2017

Figure 8 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Region, 2017

Figure 9 North America: Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Country, 2017

Figure 10 Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Country, 2017

Figure 11 Asia-Pacific: Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Country, 2017

Figure 12 Middle East & Africa: Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Country, 2017

Figure 13 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market: Company Share Analysis, 2017 (%)

Figure 14 F. Hoffmann-La Roche Ltd: Key Financials

Figure 15 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 16 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 17 GlaxoSmithKline plc: Key Financials

Figure 18 GlaxoSmithKline plc: Segmental Revenue

Figure 19 GlaxoSmithKline plc: Geographical Revenue

Figure 20 CELGENE CORPORATION: Key Financials

Figure 21 CELGENE CORPORATION: Segmental Revenue

Figure 22 CELGENE CORPORATION: Geographical Revenue

Figure 23 Genmab A/S: Key Financials

Figure 24 Genmab A/S: Segmental Revenue

Figure 25 Genmab A/S: Geographical Revenue

Figure 26 Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 27 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 28 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 29 Genentech, Inc.: Key Financials

Figure 30 Genentech, Inc.: Segmental Revenue

Figure 31 Genentech, Inc.: Geographical Revenue

Figure 32 Genzyme Corporation: Key Financials

Figure 33 Genzyme Corporation: Segmental Revenue

Figure 34 Genzyme Corporation: Geographical Revenue

Figure 35 AbbVie Inc.: Key Financials

Figure 36 AbbVie Inc.: Segmental Revenue

Figure 37 AbbVie Inc.: Geographical Revenue

Figure 38 Gilead: Key Financials

Figure 39 Gilead: Segmental Revenue

Figure 40 Gilead: Geographical Revenue

Figure 41 Novartis AG: Key Financials

Figure 42 Novartis AG: Segmental Revenue

Figure 43 Novartis AG: Geographical Revenue

Figure 44 Johnson & Johnson Services, Inc.: Key Financials

Figure 45 Johnson & Johnson Services, Inc.: Segmental Revenue

Figure 46 Johnson & Johnson Services, Inc.: Geographical Revenue

Figure 47 AstraZeneca: Key Financials

Figure 48 AstraZeneca: Segmental Revenue

Figure 49 AstraZeneca: Geographical Revenue

Figure 50 ONO PHARMACEUTICAL CO., LTD.: Key Financials

Figure 51 ONO PHARMACEUTICAL CO., LTD.: Segmental Revenue

Figure 52 ONO PHARMACEUTICAL CO., LTD.: Geographical Revenue

Figure 53 TG TREATMENT, INC.: Key Financials

Figure 54 TG TREATMENT, INC.: Segmental Revenue

Figure 55 TG TREATMENT, INC.: Geographical Revenue

Figure 56 ZIOPHARM ONCOLOGY, INC.: Key Financials

Figure 57 ZIOPHARM ONCOLOGY, INC.: Segmental Revenue

Figure 58 ZIOPHARM ONCOLOGY, INC.: Geographical Revenue